Protein therapeutics for junctional epidermolysis bullosa: incorporation of recombinant beta3 chain into laminin 332 in beta3-/- keratinocytes in vitro.

[junctional epidermolysis bullosa]

Junctional epidermolysis bullosa (JEB ) is an inherited mechanobullous disease characterized by reduced adherence of the epidermal keratinocytes to the underlying dermis , and is often caused by the absence of functional laminin 332 due to the lack or dysfunction of its beta 3 chain . As there are no specific therapies for JEB , we tested whether a protein replacement strategy could be applicable for the restoration of the laminin 332 assembly and reversion of the JEB phenotype in human keratinocytes that lack beta 3 subunit . Here , we developed the protocol for production and purification of the biologically active recombinant beta 3 chain . Next , we demonstrated that delivery of recombinant beta 3 polypeptide into the endoplasmic reticulum of the immortalized beta 3 -null keratinocytes led to the restoration of the laminin 332 assembly , secretion , and deposition into the basement membrane zone , as confirmed by Western blot analysis , confocal immunofluorescent microscopy in vitro , and on cultured organotypic human JEB skin reconstructs . Although the amount of laminin 332 produced by protein-treated beta 3 -null keratinocytes is lower than that in normal human keratinocytes , our results demonstrate the applicability of the recombinant proteins for JEB treatment and open new perspectives for the development of novel therapeutics for this inherited , currently intractable , skin disorder .

Diseases
Validation

Diseases presenting "our results demonstrate the applicability of the recombinant proteins for jeb treatment and open new perspectives for the development of novel therapeutics for this inherited" symptom

junctional epidermolysis bullosa

You can validate or delete this automatically detected symptom